3. PHARMACOLOGICAL FORM

Hand-capsule: Sustained, transparent, CON-SNAP type gelatin capsule. Radioactive pharmaceutical containing 131I-labeled iodine oxide active substance.

CLINICAL PARTICULARS

4.1 Therapeutic indications

This medicinal product is indicated for use only when there is an indication of malignancy that may be treated by radiotherapy, such as neoplasms (e.g., thyroid cancer, breast cancer, prostate cancer, or lung cancer). This product is intended to be used in the treatment of patients who have failed to respond to conventional forms of therapy, such as surgery and chemotherapy.

4.2 Posology and method of administration

Thyrop D 0.5-3.5 MBq hand-capsule is generally not recommended for the elderly or for patients with severely compromised renal or hepatic function. Thyrop D 0.5-3.5 MBq hand-capsule should be administered as a single dose on an empty stomach to the patient, and the patient should be instructed to drink a large amount of water immediately afterward. This product is intended to be used in the treatment of patients who have failed to respond to conventional forms of therapy, such as surgery and chemotherapy.

5. Pharmacological properties

4.3 Contraindications

Thyrop D 0.5-3.5 MBq hand-capsule is not recommended for the elderly or for patients with severely compromised renal or hepatic function. Thyrop D 0.5-3.5 MBq hand-capsule should be administered as a single dose on an empty stomach to the patient, and the patient should be instructed to drink a large amount of water immediately afterward. This product is intended to be used in the treatment of patients who have failed to respond to conventional forms of therapy, such as surgery and chemotherapy.

3. PHARMACOLOGICAL FORM

Hand-capsule: Sustained, transparent, CON-SNAP type gelatin capsule. Radioactive pharmaceutical containing 131I-labeled iodine oxide active substance.

CLINICAL PARTICULARS

4.1 Therapeutic indications

This medicinal product is indicated for use only when there is an indication of malignancy that may be treated by radiotherapy, such as neoplasms (e.g., thyroid cancer, breast cancer, prostate cancer, or lung cancer). This product is intended to be used in the treatment of patients who have failed to respond to conventional forms of therapy, such as surgery and chemotherapy.

4.2 Posology and method of administration

Thyrop D 0.5-3.5 MBq hand-capsule is generally not recommended for the elderly or for patients with severely compromised renal or hepatic function. Thyrop D 0.5-3.5 MBq hand-capsule should be administered as a single dose on an empty stomach to the patient, and the patient should be instructed to drink a large amount of water immediately afterward. This product is intended to be used in the treatment of patients who have failed to respond to conventional forms of therapy, such as surgery and chemotherapy.

5. Pharmacological properties

4.3 Contraindications

Thyrop D 0.5-3.5 MBq hand-capsule is not recommended for the elderly or for patients with severely compromised renal or hepatic function. Thyrop D 0.5-3.5 MBq hand-capsule should be administered as a single dose on an empty stomach to the patient, and the patient should be instructed to drink a large amount of water immediately afterward. This product is intended to be used in the treatment of patients who have failed to respond to conventional forms of therapy, such as surgery and chemotherapy.

3. PHARMACOLOGICAL FORM

Hand-capsule: Sustained, transparent, CON-SNAP type gelatin capsule. Radioactive pharmaceutical containing 131I-labeled iodine oxide active substance.

CLINICAL PARTICULARS

4.1 Therapeutic indications

This medicinal product is indicated for use only when there is an indication of malignancy that may be treated by radiotherapy, such as neoplasms (e.g., thyroid cancer, breast cancer, prostate cancer, or lung cancer). This product is intended to be used in the treatment of patients who have failed to respond to conventional forms of therapy, such as surgery and chemotherapy.

4.2 Posology and method of administration

Thyrop D 0.5-3.5 MBq hand-capsule is generally not recommended for the elderly or for patients with severely compromised renal or hepatic function. Thyrop D 0.5-3.5 MBq hand-capsule should be administered as a single dose on an empty stomach to the patient, and the patient should be instructed to drink a large amount of water immediately afterward. This product is intended to be used in the treatment of patients who have failed to respond to conventional forms of therapy, such as surgery and chemotherapy.

5. Pharmacological properties

4.3 Contraindications

Thyrop D 0.5-3.5 MBq hand-capsule is not recommended for the elderly or for patients with severely compromised renal or hepatic function. Thyrop D 0.5-3.5 MBq hand-capsule should be administered as a single dose on an empty stomach to the patient, and the patient should be instructed to drink a large amount of water immediately afterward. This product is intended to be used in the treatment of patients who have failed to respond to conventional forms of therapy, such as surgery and chemotherapy.